Thalomid and Hemiparesis - a phase IV clinical study of FDA data

Summary:

Hemiparesis is reported as a side effect among people who take Thalomid (thalidomide), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Decadron, and have Glioblastoma multiforme.

The phase IV clinical study analyzes which people have Hemiparesis when taking Thalomid. It is created by eHealthMe based on reports of 38,055 people who have side effects when taking Thalomid from the FDA, and is updated regularly.

What is Thalomid?

Thalomid has active ingredients of thalidomide. It is often used in multiple myeloma. eHealthMe is studying from 38,099 Thalomid users. Check the latest studies of Thalomid.

What is Hemiparesis?

Hemiparesis (weakness on one side of the body) is found to be associated with 1,250 drugs and 1,447 conditions by eHealthMe. Check the latest studies of Hemiparesis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

38,055 people reported to have side effects when taking Thalomid.
Among them, 65 people (0.17%) have Hemiparesis.

Among these 65 people:

How long have people been on Thalomid when they have Hemiparesis? *

What is the gender of people who have Hemiparesis when taking Thalomid? *

female: 60.94 %
male: 39.06 %

What is the age of people who have Hemiparesis when taking Thalomid? *

What are other drugs people take besides Thalomid? *

What are other side effects people have besides Hemiparesis? *

Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 13 people, 20.00%
Fall: 11 people, 16.92%
Fatigue (feeling of tiredness): 11 people, 16.92%
Speech Impairment (Adult) (inability to speak (adult)): 11 people, 16.92%
Headache (pain in head): 9 people, 13.85%
Confusional State: 8 people, 12.31%
Bell's Palsy (facial paralysis): 8 people, 12.31%
Cerebral Infarction (less blood supply to brain resulting tissue damage): 7 people, 10.77%
Disease Progression: 7 people, 10.77%
Drowsiness: 7 people, 10.77%

What are the existing conditions these people have? *

Glioblastoma Multiforme (most common and deadliest of malignant primary brain tumours in adults): 8 people, 12.31%
Glioma (a type of tumour that starts in the brain or spine): 4 people, 6.15%
Brain Neoplasm (tumour of brain): 3 people, 4.62%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 3.08%
Small Cell Lung Cancer Stage Unspecified (lung cancer in unknown stage): 1 person, 1.54%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 1.54%
Glioblastoma (most common and most aggressive malignant primary brain tumour in humans): 1 person, 1.54%
Gliosarcoma (a cancer of the brain that comes from glial, or supportive, brain cells): 1 person, 1.54%
Malignant Melanoma Site/stage Unspecified (cancer of skin un specific stage): 1 person, 1.54%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 1.54%

* Approximation only. Some reports may have incomplete information.

Do you take Thalomid and have Hemiparesis?

- Check whether Hemiparesis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Thalomid:

Thalomid (38,099 reports)

Hemiparesis treatments and more:

Hemiparesis (23,885 reports)

Browse all side effects of Thalomid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hemiparesis:

Hemiparesis (1,250 drugs)

Browse all the conditions that are associated with Hemiparesis:

Hemiparesis (1,447 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on thalidomide (the active ingredients of Thalomid) and Thalomid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.